Prostate cancer (PCa) is the most frequent diagnosed malignancy in male patients and radiation therapy (RT) is a main treatment option. However, RT concepts for PCa have an imminent need to be rectified in order to personalise the RT strategy by considering (i) the individual PCa biology and (ii) the individual disease process of each patient. The consortium concatenates a prospective, nonrandomized phase II trial for personalised RT of PCa patients (HypoFocal) with novel tools for patient involvement, advanced “omic” and bioinformatical analyses. Hereby, the implementation of novel computational components enables (i) unbiased characterisation of tumor and normal tissue biology for personalised treatment planning processes (ii) direct integration of patients’ preferences for a personalised treatment planning and follow-up process after RT.
